

# Analysts Meeting

10 November 2022



Conference Call



**RHÖN-KLINIKUM**  
AKTIENGESELLSCHAFT

# Disclaimer

This presentation has been prepared by RHÖN-KLINIKUM AG (the “**Company**”) and is for information purposes only.

This presentation does not constitute, or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company, nor shall it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever.

This presentation may contain forward-looking statements relating to the business, financial performance and results of the Company and the industry in which the Company operates. Any forward-looking statements contained in this presentation, including any assumptions, opinions and views of the Company and information attributed to or summarized from third party sources, represent solely opinions and forecasts which are subject to risks and uncertainties. Actual events may differ significantly from current expectations or assumptions due to many factors. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecasted developments. The statements in this presentation are made only as of the date of this presentation. The Company does not undertake any obligation to review, update or confirm investors’ expectations or estimates or to release publicly any revisions to any forward-looking statements given in this presentation to reflect subsequent events or circumstances that may arise in relation to the content of this presentation. Consequently, neither the delivery of this presentation nor any further discussion of the Company with any of the recipients thereof shall under any circumstances create any implication that there has been no change in the affairs of the Company since such date.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

By accepting this presentation you acknowledge the foregoing and that you will be solely responsible for your own assessment of the Company, the industry and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the current and potential future performance of the Company’s business.

Glossary: € = Euro; \$ = (US)Dollar; (F)Y = (financial) year(s); M = month(s); % = percentage; a = actual; acc. = according; approx. = approximately; e = expected; k = thousand(s); m = million(s); N/A = not applicable; RHÖN-KLINIKUM = RHÖN-KLINIKUM Aktiengesellschaft



## Management Board

- The Supervisory Board appointed **Prof. Dr. Tobias Kaltenbach** as the **new chairman** of the Management Board of RHÖN-KLINIKUM AG
- As of 1 November 2022 the **Management Board** consists of Prof. Dr. Tobias Kaltenbach (CEO), Dr. Stefan Stranz (CFO) and Dr. Gunther K. Weiß (COO)

## Business Development

- Dealing with the **COVID-19 pandemic**
- Managing the implications of the **geopolitical effects** resulting from the war in Ukraine
- Negotiations with the **Federal State of Hesse** on the **grant of investment funding** as well as on further developing the **separate accounting agreement** at **UKGM**




# Key performance figures of 9M 2022/FY 2021

Performance in € millions	9M 2022		vs. 9M 2021	FY 2021		vs. FY 2020
	Value	%		Value	%	
Revenue	1,067.3	100.0%	+3.6%	1,402.0	100.0%	+3.1%
EBITDA	76.5	7.2%	+7.6%	101.2	7.2%	+26.2%
EBIT	24.3	2.3%	+34.3%	30.5	2.2%	+187.7%
EBT	21.5	2.0%	+28.7%	27.4	2.0%	+602.6%
Consolidated profit	17.8	1.7%	+14.8%	30.2	2.2%	+1.108.0%

Detailed and comprehensive P&L in 9M 2022 statement/2021 annual report.

# Core balance sheet figures as of 9M 2022



**Solid balance sheet and sustainable financial figures**



- ✓ High equity ratio
- ✓ High net liquidity

Balance sheet figures as of 30 September 2022.

**GUIDANCE  
2022**

**Group REVENUES**

**€ 1.4bn +/- 5%**

**Group EBITDA**

**€ 92m to € 102m**

The outlook is subject to considerable uncertainties in connection with the further course of the COVID-19 pandemic and any regulatory measures impacting the remuneration structure in 2022

# Q&A Session and IR Contact



## IR Contact

### **Igor Levit**

Group Head of Accounting, Tax, Controlling, Finance & Investor Relations

### **Julian Schmitt**

Head of Investor Relations & Treasury

tel           +49 9771 65 12250  
email        ir@rhoen-klinikum-ag.com